Implementing best practice in psoriasis: A nordic expert group consensus

Acta Dermato-Venereologica

Volumn 94, Issue 5, 2014, Pages 547-552

  Kragballe, Knud ^a   Gniadecki, Robert ^b   Mørk, Nils Jørgen ^c   Rantanen, Tapio ^d   Ståhle, Mona ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Ihopiste   (Finland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Co morbidities; Nordic region; Psoriasis; Quality of life; Skin severity; Treatment goals

Indexed keywords

ARTICLE; BODY SURFACE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; COMPREHENSION; CONSENSUS; DELPHI STUDY; DERMATOLOGIST; DERMATOLOGY LIFE QUALITY INDEX; DIABETES MELLITUS; DISEASE SEVERITY; FINLAND; GENERAL PRACTITIONER; GOLD STANDARD; HUMAN; MEDICAL EDUCATION; MOTIVATION; NORWAY; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESPONSIBILITY; RISK FACTOR; SWEDEN; SYSTEMIC THERAPY; TELEPHONE INTERVIEW; TREATMENT OUTCOME; CONSENSUS DEVELOPMENT; DERMATOLOGY; PATIENT REFERRAL; REGISTER; SCANDINAVIA; SEVERITY OF ILLNESS INDEX; STANDARDS;

COMORBIDITY; DELPHI TECHNIQUE; DERMATOLOGY; HUMANS; PSORIASIS; QUALITY OF LIFE; REFERRAL AND CONSULTATION; REGISTRIES; SCANDINAVIAN AND NORDIC COUNTRIES; SEVERITY OF ILLNESS INDEX;

EID: 84906056414     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1809     Document Type: Article

References (23)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
2. Villasenor-Park J, Wheeler D, Grandinetti L. Psoriasis: evolving treatment for a complex disease. Cleve Clin J Med 2012; 79: 413-423.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
4. Khalid U, Hansen PR, Gislason GH, Lindhardsen J, Kristensen SL, Winther SA, et al. Psoriasis and new-onset diabetes: A Danish nationwide cohort study. Diabetes Care 2013; 36: 2402-2407.
5. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775. e771-775.
6. Ahlehoff O. Psoriasis and cardiovascular disease: epidemiological studies. Dan Med Bull 2011; 58: B4347.
7. The Danish Society of Dermatology. Guidelines for the treatment of psoriasis with biologics. 2012; http://www. dds.nu/index.php?p=13 Accessed July 2, 2013.
8. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
9. British Association of Dermatologists & Primary Care Dermatology Society. Recommendations for the initial management of psoriasis. 2009; http://www.bad.org.uk/ Portals/_Bad/Guidelines/Clinical%20Guidelines/BADPCDS% 20Psoriasis%20reviewed%202010.pdf. Accessed March 22, 2013.
10. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 Suppl 2: 1-70.
11. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
12. Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One 2012; 7: e36342.
13. Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 67: 76-85.
14. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
15. Augustin M, Alvaro-Gracia JM, Bagot M, Hillmann O, van de Kerkhof PC, Kobelt G, et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26 Suppl 4: 1-16.
16. Fried RG, Friedman S, Paradis C, Hatch M, Lynfield Y, Duncanson C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995; 34: 101-105.
17. Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-157.
18. PSONET. European surveillance network to monitor the long term effectiveness and safety of systemic agents in the treatment of psoriasis. The PSONET Code of Conduct. 2011; http://www.psonet.eu/cms/public/files/code_of_conduct_ 20.04.2011.pdf. Accessed March 22, 2013.
19. Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC. Standardizing training for psoriasis measures: effectiveness of an online training video on psoriasis area and severity index assessment by physician and patient raters. JAMA Dermatol 2013; 149: 577-582.
20. Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkila H, Jemec GB, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol 2013; 93: 442-445.
21. Bundy C, Pinder B, Bucci S, Reeves D, Griffiths CE, Tarrier N. A novel, web-based, psychological intervention for people with psoriasis: The electronic targeted intervention for psoriasis (eTIPs) study. Br J Dermatol 2013; 169: 329-336.
22. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
23. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.